Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IONS with free AI briefings, catalyst countdowns, and dilution alerts.

IONS · IONIS PHARMACEUTICALS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.4B Cash on Hand
CF+ Cash Runway
16.8% Short Interest
$67.83 Analyst Target (23)
Follow IONS by email Get an email when IONS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IONS, unsubscribe in one click. Privacy

📣 What IONS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Donidalorsen
FDA approved Aug 2025 · Dawnzera (Autoinjector)
Hereditary Angioedema Phase 3 · NCT05392114 Active not recruiting
Zilganersen
FDA approved Sep 2026 · Zanvastro
Alexander Disease Phase 3 · NCT04849741 Active not recruiting
Olezarsen
FDA approved Dec 2024 · Tryngolza (Autoinjector)
Severe Hypertriglyceridemia Phase 3 · NCT05681351 Active not recruiting
Obudanersen Angelman Syndrome Phase 3 · NCT07782827 Recruiting
ION363 Amyotrophic Lateral Sclerosis Phase 3 · NCT04768972 Active not recruiting
Inotersen Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Phase 3 · NCT04136184 Completed
ION337 Dravet Syndrome Phase 1/2 · NCT07531745 Recruiting
ION440 Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome Phase 1/2 · NCT06430385 Recruiting
ION582 Angelman Syndrome Phase 1/2 · NCT05127226 Active not recruiting
ION717 Prion Disease Phase 1/2 · NCT06153966 Active not recruiting
ION775 Hypertriglyceridemia Phase 2 · NCT07604974 Recruiting
IONIS-AGT-LRx Hypertension Phase 2 · NCT04714320 Completed
IONIS-FB-LRx Macular Degeneration Phase 2 · NCT03815825 Completed
ION224 Steatohepatitis, Nonalcoholic Phase 2 · NCT04932512 Completed
Sapablursen Phlebotomy Dependent Polycythemia Vera Phase 2 · NCT05143957 Completed
ION356 Pelizaeus-Merzbacher Disease Phase 1 · NCT06150716 Recruiting

Also used in these trials (approved or third-party drugs, not IONS's own candidates): Tofersen, Eplontersen.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IONS holds $2.4B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IONS files for a raise →

👥 Who Owns IONS

Insiders 0.7% Institutions (667 holders) 99.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR, LLC Institution (13F) 24,740,108 14.85% 2026-09-30
Capital World Investors Institution (13G, 5%+) 21,186,369 12.72% 2026-03-31
Blackrock Inc. Institution (13F) 13,192,834 7.92% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 8,344,732 5.01% 2026-03-31
Vanguard Portfolio Management LLC Institution (13F) 7,719,464 4.64% 2026-09-30
Two Sigma Investments, LP Institution (13F) 6,727,410 4.04% 2026-09-30
State Street Corporation Institution (13F) 5,710,900 3.43% 2026-09-30
Citadel Advisors Llc Institution (13F) 4,026,275 2.42% 2026-09-30
Wellington Management Group, LLP Institution (13F) 3,430,545 2.06% 2026-09-30
Brett P Monia
Chief Executive Officer, Director · +1.05M options
Insider 242,760 0.15% 2026-08-31
Spencer R Berthelsen
Director · +7,670 options
Insider 161,303 0.10% 2026-07-15
Brian Birchler
EVP, Corp and Development Ops · +48,926 options
Insider 102,883 0.06% 2026-08-31

Share count 166,545,100 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-13
Hayden Michael R
Purchase (P) 5,000 $29.64 27,000
2026-08-31
filed 2026-09-02
O'NEIL PATRICK R.
Other (J) 63 $51.31 59,205
2026-08-31
filed 2026-09-02
BENNETT C FRANK
Other (J) 110 $51.31 60,128
2026-08-31
filed 2026-09-02
Monia Brett P
Other (J) 98 $51.31 242,760
2026-08-31
filed 2026-09-02
Birchler Brian
Other (J) 58 $51.31 102,883

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-10-21 Hibsago (bepirovirsen) NDA +1.1% -2.5% —
2026-09-22 — NDA -23.6% -2.2% —
2025-08-21 — NDA +2.1% +1% -0.1%

Browse all historical PDUFA outcomes →

Get the full IONS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IONS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.